A Case of Graft Replacement of Abdominal Aortic Aneurysm in Congenital Deficiency of Coagulation Factor XIII.
	    		
	    			
	    			
		        		
			        		
		        		
			        
		   		
		   		
		   			
		   		
	    	
    	 
    	10.4326/jjcvs.27.59
   		
        
        	
        		- VernacularTitle:先天性XIII因子欠乏症を伴った腹部大動脈りゅうに対する一治験例
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Noriyuki Murai
			        		
			        		;
		        		
		        		
		        		
			        		Tatsuo Kaneko
			        		
			        		;
		        		
		        		
		        		
			        		Tamiyuki Obayashi
			        		
			        		;
		        		
		        		
		        		
			        		Yasushi Satou
			        		
			        		;
		        		
		        		
		        		
			        		Toshiro Ogata
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Journal Article
 
        	
        	
            
            
            	- From:Japanese Journal of Cardiovascular Surgery
	            		
	            		 1998;27(1):59-62
	            	
            	
 
            
            
            	- CountryJapan
 
            
            
            	- Language:Japanese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	No case of graft replacement for abdominal aortic aneurysm in a case of congenital deficiency of coagulation factor X III has yet been reported. Recently we performed graft replacement of 66-year-old man with congenital deficiency of coagulation factor X III. Concentrated factor X III separated from human placenta (Fibrogamin®) was used during, before and after the operation. We measured factor X III activity, and when the activity was so low that replacement therapy was necessary, we administered Fibrogamin immediately. We maintained coagulation factor X III activity at over 70%. No adverse reaction of factor X III replacement therapy was observed. The postoperative course was uneventful and the patient did not have delayed wound healing.